FindTrial
Sign In

Samotolisib

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaHistiocytic SarcomaJuvenile XanthogranulomaLangerhans Cell HistiocytosisMalignant GliomaRecurrent Childhood Rhabdomyosarcoma

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Active, not recruitingNCT03155620
National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma +42
Start: 2017-07-31End: 2027-01-06Updated: 2026-02-10
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
CompletedNCT03213678
National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma +30
Start: 2017-11-28End: 2024-12-31Updated: 2026-04-02

Related Papers

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist2024-05-306 citations
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.
Journal of Clinical Oncology2023-06-013 citations
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
2022-06-077 citations
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
The Oncologist2022-04-1445 citations
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Cancer Discovery2022-03-16143 citations
Abstract 631: Germline cancer predisposition results from the National Cancer Institute - Children's Oncology Group (NCI-COG) Pediatric MATCH Trial
Cancer Research2021-07-01
Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.
Journal of Clinical Oncology2021-05-203 citations
Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.
Journal of Clinical Oncology2021-05-202 citations
Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.
Journal of Clinical Oncology2019-05-2032 citations